According to a recent LinkedIn post from Levee Medical, Johns Hopkins Hospital and Dr. Arun Rai have enrolled their first patient in the ARID II IDE pivotal trial. The trial is described as focused on evaluating the Voro® Urologic Scaffold and its impact on early and long-term continence following prostate surgery.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests that this enrollment marks a key progression in the clinical evaluation of Levee Medical’s technology, moving it deeper into pivotal-stage evidence generation. For investors, successful advancement and positive outcomes from ARID II could strengthen the value proposition of the Voro platform, support future regulatory pathways, and enhance Levee Medical’s positioning in the post-prostatectomy care segment.
The involvement of a major institution like Johns Hopkins may also signal growing clinical interest in solutions addressing continence outcomes after prostate surgery. If the trial produces favorable data, it could improve the company’s prospects for adoption, reimbursement discussions, and potential strategic partnering in the urology and surgical devices market.